Othera Pharmaceuticals Files IND Application for OT-730 in Glaucoma
7/30/2008 9:41:26 AM
EXTON, Pa.--(BUSINESS WIRE)--Othera Pharmaceuticals, Inc., announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for OT-730, an oculoselective beta-blocker, as a potential treatment for glaucoma. A Phase 1-2 safety and efficacy trial is planned for completion by the end of 2008.
comments powered by